Farallon Capital Funds Disclose Over $114M in EXELIXIS Share Sales

summarizeSummary

Farallon Capital Management's funds disclosed significant selling activity of EXELIXIS, INC. common stock over the past 60 days, with one key fund reducing its position by nearly 30%. This Schedule 13D/A also updated the beneficial ownership due to internal personnel changes within Farallon.

check_boxKey Events

• Significant Share Sales Disclosed

  Farallon Capital Management's funds reported substantial sales of EXELIXIS, INC. common stock over the last 60 days, totaling over $114 million from one key fund alone.

• Major Fund Reduces Stake

  Farallon Healthcare Partners Master, L.P., a key fund within the Farallon group, sold approximately 2.7 million shares, representing nearly 30% of its previous holdings in EXELIXIS, INC.

• Internal Personnel Changes

  The filing updated the list of beneficial owners due to internal management changes at Farallon Capital Management, including one new member and three departures from managing roles.

auto_awesomeAnalysis

This amended Schedule 13D from Farallon Capital Management, a significant institutional investor, reveals substantial selling activity in EXELIXIS, INC. shares by its affiliated funds over the past two months. The most notable transaction involves Farallon Healthcare Partners Master, L.P., which reduced its position by approximately 2.7 million shares, valued at over $114 million, representing nearly 30% of its previous holdings. While the filing also details administrative changes in Farallon's management, the disclosure of such a large-scale reduction by a major investor could signal a shift in their investment thesis or a rebalancing of their portfolio, which warrants close attention from other investors.